Literature DB >> 24166504

Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration.

C J De Saedeleer1, P E Porporato1, T Copetti1, J Pérez-Escuredo1, V L Payen1, L Brisson1, O Feron1, P Sonveaux1.   

Abstract

The glycolytic end-product lactate is a pleiotropic tumor growth-promoting factor. Its activities primarily depend on its uptake, a process facilitated by the lactate-proton symporter monocarboxylate transporter 1 (MCT1). Therefore, targeting the transporter or its chaperon protein CD147/basigin, itself involved in the aggressive malignant phenotype, is an attractive therapeutic option for cancer, but basic information is still lacking regarding the regulation of the expression, interaction and activities of both proteins. In this study, we found that glucose deprivation dose-dependently upregulates MCT1 and CD147 protein expression and their interaction in oxidative tumor cells. While this posttranslational induction could be recapitulated using glycolysis inhibition, hypoxia, oxidative phosphorylation (OXPHOS) inhibitor rotenone or hydrogen peroxide, it was blocked with alternative oxidative substrates and specific antioxidants, pointing out at a mitochondrial control. Indeed, we found that the stabilization of MCT1 and CD147 proteins upon glucose removal depends on mitochondrial impairment and the associated generation of reactive oxygen species. When glucose was a limited resource (a situation occurring naturally or during the treatment of many tumors), MCT1-CD147 heterocomplexes accumulated, including in cell protrusions of the plasma membrane. It endowed oxidative tumor cells with increased migratory capacities towards glucose. Migration increased in cells overexpressing MCT1 and CD147, but it was inhibited in glucose-starved cells provided with an alternative oxidative fuel, treated with an antioxidant, lacking MCT1 expression, or submitted to pharmacological MCT1 inhibition. While our study identifies the mitochondrion as a glucose sensor promoting tumor cell migration, MCT1 is also revealed as a transducer of this response, providing a new rationale for the use of MCT1 inhibitors in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166504     DOI: 10.1038/onc.2013.454

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.

Authors:  Chunxiao Yan; Fan Yang; Chunxia Zhou; Xuejun Chen; Xuechuan Han; Xueqin Liu; Hongyun Ma; Wei Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Metabolic implication of tumor:stroma crosstalk in breast cancer.

Authors:  Andrea Morandi; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2014-01-24       Impact factor: 4.599

3.  [Small interfering RNA-mediated monocarboxylate transporter 1 silencing enhances sensitivity of nasopharyngeal carcinoma HNE1/DDP cells to cisplatin-induced apoptosis].

Authors:  Pei Zhang; Fang Liu; Jiao Gao; Lin-Yan Ma; Xiao-Jin Sun; Hai-Lun Zheng; Hao Liu; Su-Rong Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

Review 4.  Alternative fuels for cancer cells.

Authors:  Melissa M Keenan; Jen-Tsan Chi
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

Review 5.  Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.

Authors:  Valéry L Payen; Paolo E Porporato; Bjorn Baselet; Pierre Sonveaux
Journal:  Cell Mol Life Sci       Date:  2015-12-01       Impact factor: 9.261

Review 6.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

7.  A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth.

Authors:  Henk M De Feyter; Kevin L Behar; Jyotsna U Rao; Kirby Madden-Hennessey; Kevan L Ip; Fahmeed Hyder; Lester R Drewes; Jean-François Geschwind; Robin A de Graaf; Douglas L Rothman
Journal:  Neuro Oncol       Date:  2016-05-03       Impact factor: 12.300

Review 8.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Lactate promotes glutamine uptake and metabolism in oxidative cancer cells.

Authors:  Jhudit Pérez-Escuredo; Rajesh K Dadhich; Suveera Dhup; Andrea Cacace; Vincent F Van Hée; Christophe J De Saedeleer; Martina Sboarina; Fabien Rodriguez; Marie-Joséphine Fontenille; Lucie Brisson; Paolo E Porporato; Pierre Sonveaux
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

10.  Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma.

Authors:  Mahasweta Gooptu; Diana Whitaker-Menezes; John Sprandio; Marina Domingo-Vidal; Zhao Lin; Guldeep Uppal; Jerald Gong; Roberto Fratamico; Benjamin Leiby; Alina Dulau-Florea; Jaime Caro; Ubaldo Martinez-Outschoorn
Journal:  Semin Oncol       Date:  2017-10-10       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.